Walgreens Boots Alliance sold to private equity firm - will Boots get the boot?
US pharmacy giant Walgreens Boots Alliance is going private. Will the new owners sell off the high-street chemist?


Recently, Walgreens Boots Alliance struck a deal with private-equity group Sycamore Partners that will “bring the struggling pharmacy chain’s century-long run as a public company to an end”, says the Financial Times. Sycamore agreed to pay $11.45 a share, a premium of almost 30% to the price before news of a possible deal emerged in December. Sycamore is valuing the business, including its debt, at $23.7 billion. Billionaire Stefano Pessina, Walgreens’ executive chairman and largest shareholder, will maintain a “sizeable minority shareholding” in the business.
Despite retaining a stake, the deal is a blow for Pessina. He “spent half a century building a pharmacy behemoth that stretches almost three times further than the Roman empire ever did”, says Benjamin Katz in The Wall Street Journal. After turning around and expanding his father’s “fledgling and failing pharmaceutical wholesaler”, he merged it with UniChem in 1997 and bought Boots in 2006. That combination was in turn acquired by Walgreens in 2014, creating a conglomerate with a peak market value in excess of $100 billion. However, it struggled with Amazon “quickly eating into drugstores’ non-medical revenues”. This forced it to cancel its dividend and slash the store’s portfolio.
What does the Walgreens sale mean for Boots?
Walgreens proved unable to deal with the challenges posed by both Amazon and “big-box retailers, such as Walmart and Target”, says Chris Isidore on CNN; “lower reimbursement rates for prescription drugs” in the United States hardly helped matters. However, despite claims that Sycamore’s “strong... record of successful retail turnarounds” will help turn Walgreens around, “retail’s graveyard is full of the bones of many once-dominant retailers who closed up shop after being bought by private-equity firms”. At the very least, “the fundamental problems leading to the private-equity purchase” won’t go away after this deal.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The fact that Sycamore is using up to $12 billion of leverage to push through the deal will make it even harder for Walgreen’s “miserable decade” to be reversed, says Robert Cyran for Breakingviews. The added debt (assuming a 10% interest rate) will more than double Walgreen’s interest payments, eating into the $1.8 billion in operating profit it is currently making – sharply down from $7 billion in 2018. Far from buying the company to turn it around, Sycamore seems to be aiming at “dismantling it further by splitting out units [such as] Boots”.
The sale “could lay the groundwork for Boots to be relisted or sold out from under its parent”, says Laith Al-Khalaf in The Sunday Times. It makes “little commercial sense” for a US retailer to “retain a UK-centric pharmacy”, especially since there is a feeling that the parent company “has chronically underinvested in Boots”. Still, with 8.1% like-for-like sales growth in the latest quarter, and 15 quarters of rising market share, Boots “is very important for Walgreens”. Sycamore may decide that the best bet is for Boots to remain part of the overall group.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
HMRC confirms crypto ETN ISA rules
With crypto ETNs now technically available for UK retail investors, HMRC has confirmed they can be held in an ISA – but there’s a complication
-
Pensioners targeted in fine wine scams – the tactics to watch for
Wine has emerged as the latest lure in investment fraud, with pensioners being specifically targeted by scammers
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
-
The Palace of Westminster is falling down
The Palace of Westminster is in need of repair, but the bill is prohibitive, says Simon Wilson
-
'Gen Z is facing an AI jobs bloodbath'
Opinion It has always been tough to get your first job, but this year, it's proving tougher than ever. AI is to blame, says Matthew Lynn
-
Should the Online Safety Act survive?
The Online Safety Act, a measure to safeguard children, is having unintended consequences
-
The secret behind Sweden’s success
Opinion Sweden's stock market is in rude health, says Max King. Why can't Britain follow suit?
-
Prabowo Subianto: Indonesia’s Deng Xiaoping
Prabowo Subianto, like his Chinese hero, is taking power in his 70s with big ambitions for his country. Yet many view his return to politics with dread